Therefore, S100A6 immunohistochemistry could represent a novel marker for basal cells in the benign prostate and its absence in malignant cells may be useful as an adjuvant method to p63 and 34βE12 immunostaining to facilitate the pathological diagnosis of prostate cancer. Here, S100A6 is linked to urogenital neoplasm.